Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.
暂无分享,去创建一个
B. Tönshoff | J. Chapman | D. Cattaneo | D. Holt | S. Tett | D. Kuypers | Y. Le Meur | T. Gelder | M. Cantarovich | M. Tredger
[1] Á. Alonso,et al. POPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID: A COMPARISON BETWEEN ENTERIC-COATED MYCOPHENOLATE SODIUM AND MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS: 2607 , 2010 .
[2] J. D. de Fijter,et al. Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid , 2010, Transplantation.
[3] M. H. Ensom,et al. Limited Sampling Strategies for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Islet Transplant Recipients , 2010, The Annals of pharmacotherapy.
[4] L. Essioux,et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism , 2009, Pharmacogenetics and genomics.
[5] S. Mulgaonkar,et al. Fixed‐ or Controlled‐Dose Mycophenolate Mofetil with Standard‐ or Reduced‐Dose Calcineurin Inhibitors: The Opticept Trial , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] F. Oppenheimer,et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] G. Steinbeck,et al. Proton Pump Inhibitors Reduce Mycophenolate Exposure in Heart Transplant Recipients—A Prospective Case‐Controlled Study , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] K. Budde,et al. Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells , 2009, Therapeutic drug monitoring.
[9] K. Budde,et al. Clinical Utility of a New Enzymatic Assay for Determination of Mycophenolic Acid in Comparison With an Optimized LC-MS/MS Method , 2009, Therapeutic drug monitoring.
[10] J. D. de Fijter,et al. Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial , 2008, Transplantation.
[11] L. Weber,et al. Long-Term Pharmacokinetics of Mycophenolic Acid in Pediatric Renal Transplant Recipients Over 3 Years Posttransplant , 2008, Therapeutic drug monitoring.
[12] T. Habuchi,et al. Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients , 2008, Therapeutic drug monitoring.
[13] B. Meiser,et al. Defining Algorithms for Efficient Therapeutic Drug Monitoring of Mycophenolate Mofetil in Heart Transplant Recipients , 2008, Therapeutic drug monitoring.
[14] C. Bing,et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: Prediction of occurrence of leukopenia , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[15] L. Shaw,et al. Multicenter Evaluation of a New Inosine Monophosphate Dehydrogenase Inhibition Assay for Quantification of Total Mycophenolic Acid in Plasma , 2008, Therapeutic drug monitoring.
[16] M. H. Ensom,et al. Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction? , 2008, The Annals of pharmacotherapy.
[17] K. Budde,et al. PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISON OF AN INITIALLY INTENSIFIED DOSING REGIMEN VERSUS A STANDARD DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT PATIENTS.: 717 , 2008 .
[18] C. Sommerer,et al. COMPARISON OF AN INITIALLY INTENSIFIED DOSING REGIMEN VERSUS A STANDARD DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT PATIENTS: EFFICACY AND SAFETY ANALYSIS OF 75 PATIENTS.: 266 , 2008 .
[19] S. Knight,et al. Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review , 2008, Transplantation.
[20] J. Tolar,et al. Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT) , 2008, Journal of clinical pharmacology.
[21] D. Kuypers,et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. , 2008, Clinical Therapeutics.
[22] K. Verbeke,et al. Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[23] A. Ignaszewski,et al. Performance of limited sampling strategies for predicting mycophenolic acid area under the curve in thoracic transplant recipients. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[24] T. Habuchi,et al. Influence of Lansoprazole and Rabeprazole on Mycophenolic Acid Pharmacokinetics One Year After Renal Transplantation , 2008, Therapeutic drug monitoring.
[25] L. Hongwei,et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[26] P. Marquet,et al. Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] 田中 寿和,et al. 90)BMSの再狭窄後にDESを留置しfructureを起こした1例(第129回日本循環器学会東海地方会) , 2007 .
[28] C. Guillemette,et al. Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[29] D. Kuypers,et al. The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide , 2007, Transplantation.
[30] J. D. de Fijter,et al. Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] N. Oda,et al. Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[32] T. Kwong,et al. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[33] R. Boulieu,et al. Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[34] U. Christians,et al. Pharmacokinetics of enteric‐coated mycophenolate sodium in stable liver transplant recipients , 2007, Clinical transplantation.
[35] M. Mihatsch,et al. Five-Year Outcome in Pediatric Patients With Mycophenolate Mofetil-Based Renal Transplantation , 2007, Transplantation.
[36] K. Budde,et al. Pharmacokinetic and Pharmacodynamic Comparison of Enteric‐Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[37] G. Iaria,et al. Switch to 1.5 grams MMF monotherapy for CNI‐related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[38] D. Holt,et al. Bioequivalence of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: A Meta-Analysis of Three Studies in Stable Renal Transplant Recipients , 2006, Transplantation.
[39] U. Neumann,et al. Mycophenolate mofetil in liver transplantation – is monotherapy safe? , 2006, Clinical transplantation.
[40] L. Weber,et al. Validation of an Abbreviated Pharmacokinetic Profile for the Estimation of Mycophenolic Acid Exposure in Pediatric Renal Transplant Recipients* , 2006, Therapeutic drug monitoring.
[41] R. Morris,et al. CEDIA® Mycophenolic Acid Assay Compared With HPLC-UV in Specimens From Transplant Recipients , 2006, Therapeutic drug monitoring.
[42] V. Armstrong,et al. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. , 2006, Clinical chemistry.
[43] G. Filler. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation * , 2006, Pediatric transplantation.
[44] R. Levy,et al. Limited Sampling Strategy for Predicting Area Under the Concentration‐Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients , 2006, Pharmacotherapy.
[45] M. Molimard,et al. Fully Automated Analytical Method for Mycophenolic Acid Quantification in Human Plasma Using On-line Solid Phase Extraction and High Performance Liquid Chromatography With Diode Array Detection , 2006, Therapeutic drug monitoring.
[46] N. Perico,et al. PHARMACOKINETICS OF MYCOPHENOLATE SODIUM AND COMPARISON WITH THE MOFETIL FORMULATION IN KIDNEY TRANSPLANT RECIPIENTS. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[47] Mary H. H. Ensom,et al. Beyond Cyclosporine: A Systematic Review of Limited Sampling Strategies for Other Immunosuppressants , 2006, Therapeutic drug monitoring.
[48] A. Remppis,et al. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. , 2006, Clinical therapeutics.
[49] L. Shaw,et al. Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation , 2006, Therapeutic drug monitoring.
[50] A. Prémaud,et al. Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatography–Tandem Mass Spectrometry , 2006, Therapeutic drug monitoring.
[51] M. Pescovitz,et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. , 2006, Journal of the American Society of Nephrology : JASN.
[52] J. Martorell.,et al. Sequential Determination of Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Liver Transplant Patients Treated with Mycophenolate Mofetil , 2006, Transplantation.
[53] F. Akhlaghi,et al. High-Performance Liquid Chromatography Method for the Determination of Mycophenolic Acid and Its Acyl and Phenol Glucuronide Metabolites in Human Plasma , 2006, Therapeutic drug monitoring.
[54] R. Borrows,et al. Mycophenolic Acid 12‐h Trough Level Monitoring in Renal Transplantation: Association with Acute Rejection and Toxicity , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[55] M. Sarwal,et al. Mycophenolate Mofetil in Pediatric Renal Transplantation , 2005, Transplantation.
[56] N. Giannetti,et al. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[57] S. Vermeire,et al. The impact of uridine diphosphate–glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single‐nucleotide polymorphisms T—275A and C—2152T on early mycophenolic acid dose‐interval exposure in de novo renal allograft recipients , 2005, Clinical pharmacology and therapeutics.
[58] L. Weber,et al. Mycophenolate mofetil suspension in pediatric renal transplantation: Three‐year data from the tricontinental trial , 2005, Pediatric transplantation.
[59] M. Copin,et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. , 2005, Journal of the American Society of Nephrology : JASN.
[60] P. Clavien,et al. Mycophenolate Mofetil for Renal Dysfunction in Liver Transplant Recipients on Cyclosporine or Tacrolimus: Randomized, Prospective, Multicenter Pilot Study Results , 2005, Transplantation.
[61] G. Verleden,et al. Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate‐glucuronosyltransferase , 2005, Clinical pharmacology and therapeutics.
[62] A. Prémaud,et al. Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods , 2005, Therapeutic drug monitoring.
[63] M. Isola,et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. , 2005, Transplantation proceedings.
[64] W. Arns,et al. Enteric‐coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil , 2005, Clinical transplantation.
[65] G. Vallejo,et al. Improved long‐term allograft function in pediatric renal transplantation with mycophenolate mofetil , 2005, Pediatric Transplantation.
[66] P. Taylor. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. , 2005, Clinical biochemistry.
[67] T. Stijnen,et al. Improved outcome of pediatric kidney transplantations in the Netherlands – Effect of the introduction of mycophenolate mofetil? , 2005, Pediatric transplantation.
[68] E. Heinzen,et al. The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil , 2005, Journal of clinical pharmacology.
[69] W. Nahas,et al. The need of mycophenolic acid monitoring in long‐term renal transplants , 2005, Clinical transplantation.
[70] K. Budde,et al. Pre‐Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[71] I. Millán,et al. Mycophenolate Mofetil Can Be Used as Monotherapy Late After Liver Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[72] T. Hirano,et al. Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.
[73] B. Maes,et al. Clinical Efficacy and Toxicity Profile of Tacrolimus and Mycophenolic Acid in Relation to Combined Long‐term Pharmacokinetics in de Novo Renal Allograft Recipients , 2004, Clinical pharmacology and therapeutics.
[74] C. Gonde,et al. Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[75] G. Filler. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy , 2004, Transplant international : official journal of the European Society for Organ Transplantation.
[76] David W. Johnson,et al. Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[77] M. Pescovitz,et al. Equivalent Pharmacokinetics of Mycophenolate Mofetil in African‐American and Caucasian Male and Female Stable Renal Allograft Recipients , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[78] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[79] R. Wolfe,et al. Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.
[80] J. Barkun,et al. EFFICACY OF MYCOPHENOLATE MOFETIL COMBINED WITH VERY LOW‐DOSE CYCLOSPORINE MICROEMULSION IN LONG‐TERM LIVER‐TRANSPLANT PATIENTS WITH RENAL DYSFUNCTION , 2003, Transplantation.
[81] L. Shaw,et al. Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[82] M. Mihatsch,et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years1,2 , 2003, Transplantation.
[83] W. Nahas,et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation , 2003, Pediatric Nephrology.
[84] S. Hunt,et al. Mycophenolic acid concentrations in long‐term heart transplant patients: relationship with calcineurin antagonists and acute rejection , 2002, Clinical transplantation.
[85] L. Weber,et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. , 2002, Journal of the American Society of Nephrology : JASN.
[86] L. Weber,et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. , 2002, Clinical chemistry.
[87] A. Demetris,et al. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[88] B. Chavers,et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients , 2001, Pediatric Nephrology.
[89] K. Budde,et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. , 2001, Clinical biochemistry.
[90] T. Starzl,et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. , 2001, Transplantation.
[91] V. Armstrong,et al. Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. , 2001, Clinical chemistry.
[92] L. Shaw,et al. Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion , 2001, Therapeutic drug monitoring.
[93] H. Poulsen,et al. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[94] G. Klintmalm,et al. A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[95] W. Weimar,et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. , 2001, Transplantation proceedings.
[96] L. Weber,et al. MYCOPHENOLATE MOFETIL IN PEDIATRIC RENAL TRANSPLANTATION WITHOUT INDUCTION THERAPY: RESULTS AFTER 12 MONTHS OF TREATMENT1,2 , 2001, Transplantation.
[97] R. Tukey,et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes , 2001, British journal of pharmacology.
[98] E. Schütz,et al. A NOVEL MANAGEMENT STRATEGY OF STEROID-FREE IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION: EFFICACY AND SAFETY OF TACROLIMUS AND MYCOPHENOLATE MOFETIL , 2001, Transplantation.
[99] L. Shaw,et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[100] S. Tett,et al. Evaluation of Limited Sampling Strategies for Estimation of 12-Hour Mycophenolic Acid Area Under the Plasma Concentration–Time Curve in Adult Renal Transplant Patients , 2000, Therapeutic drug monitoring.
[101] N. Smedira,et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. , 2000, Transplantation.
[102] A. Tsaroucha,et al. Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapy. , 2000, Transplant immunology.
[103] G. Filler,et al. Limited sampling strategy for mycophenolic acid area under the curve. , 2000, Therapeutic drug monitoring.
[104] V. Armstrong,et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. , 2000, Clinical chemistry.
[105] G. Filler,et al. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression , 2000, Pediatric Nephrology.
[106] D. Deming,et al. MYCOPHENOLATE MOFETIL (MMF) IN PEDIATRIC RENAL TRANSPLANTATION , 1999 .
[107] V. Armstrong,et al. Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil , 1999, British journal of pharmacology.
[108] H. Reichenspurner,et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[109] V. Armstrong,et al. How to handle mycophenolate mofetil in combination with tacrolimus? , 1998, Transplantation proceedings.
[110] D. Renlund,et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. , 1998, Transplantation.
[111] L. Shaw,et al. Therapeutic monitoring of mycophenolic acid: A consensus panel report , 1998 .
[112] A. Nicholls,et al. Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.
[113] J. Squifflet,et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. , 1998, Transplantation.
[114] T. Tarnowski,et al. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma. , 1996, Journal of chromatography. B, Biomedical applications.
[115] B. Nashan,et al. Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients , 2009, Clinical pharmacokinetics.
[116] Peter Shaw,et al. HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. , 2009, Biomedical chromatography : BMC.
[117] Ewert Bengtsson,et al. Annual Report 2008 , 2009 .
[118] R. Geskus,et al. Transition to the adult nephrologist does not induce acute transplant rejection , 2009 .
[119] G. Gerosa,et al. Pharmacokinetics and variability of mycophenolic acid from enteric‐coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients , 2007, Clinical transplantation.
[120] W. Qiu,et al. Pharmacokinetics of Mycophenolic Acid and Determination of Area Under the Curve by Abbreviated Sampling Strategy in Chinese Liver Transplant Recipients , 2007, Clinical pharmacokinetics.
[121] C. Staatz,et al. Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients , 2007, Clinical pharmacokinetics.
[122] A. Prémaud,et al. A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil , 2005, Clinical pharmacokinetics.
[123] J. Squifflet,et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. , 2001, Clinical chemistry.
[124] L. Weber,et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group. , 2001, Transplantation.
[125] Acad Sci,et al. A NOVEL MANAGEMENT STRATEGY OF STEROID-FREE IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION: EFFICACY AND SAFETY OF TACROLIMUS AND MYCOPHENOLATE MOFETIL , 2001 .
[126] L. Weber,et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.